The global M&A market is booming. Bill Mordan, general counsel at FTSE 100 drug-maker Shire, would know. Shire’s board recently recommended a £46bn takeover offer from rival Japanese pharma giant Takeda.
‘Money continues to be cheap to borrow and so it’s still easy to get funding from venture capital, as well as other speciality equity investments in new technologies,’ Mordan comments. ‘There’s a large quantum of assets out there available for acquisition.’